Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Deepak L Bhatt Added: 1 month ago
American College of Cardiology Congress 2026 – Dr Deepak Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us to discuss primary results from the MOMENTUM study (NCT06829537; Corcept Therapeutics) investigating the prevalence and clinical impact of endogenous hypercortisolism in patients with resistant hypertension.This prospective, cross-sectional observational study enrolled 1,143… View more
Author(s): Harriette Van Spall , Luke Laffin Added: 1 year ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more
Author(s): Rhian Touyz Added: 1 year ago
ESC Congress 2024 — Dr Rhian Touyz (McGill University Health Center, CA) joins us to discuss key highlights from the ESC 2024 guidelines for the management of elevated blood pressure and hypertension.The new guidelines introduce a new systolic blood pressure treatment target range of 120-129 mmHg, placing emphasis on an intensive target treatment as the first step in patient management - only… View more
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 1 year ago
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the… View more
Author(s): Purvi Parwani Added: 1 month ago
Dr Purvi Parwani (Loma Linda University Health, US) recaps the standout science from Day 2 of ACC 2026, a day defined by a central theme: challenging long-held assumptions in cardiology. Her summary focuses on what these updates mean for day-to-day clinical practice, from prevention strategies to interventional decision-making.Prevention and Risk ReductionVESALIUS-CV: Showed a 25% reduction in… View more
Professor Melvin Lobo is a Consultant Physician based in St Bartholomew’s Hospital and the William Harvey Research Institute. He has a specialist interest in blood pressure disorders of all types, autonomic control of the circulation and also resistant hypertension and device-based therapies. View more
Research Area(s) / Expertise:
Dr Indranil Dasgupta is a Consultant Nephrologist at Heart of England NHS Foundation Trust, and is an Honorary Senior Lecturer at the University of Birmingham, UK. His research interests include treatment resistant hypertension. Dr Dasgupta is Clinical Research Lead Division 2 for Renal, Stroke, CVD, Diabetes and Metabolic Diseases for the West Midlands in NIHR Clinical Research Network, Honorary… View more
Research Area(s) / Expertise: Job title: Preventive Cardiologist
Dr Luke Laffin is a physician in the Preventive Cardiology & Rehabilitation Section in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart & Vascular Institute. He sees patients at Cleveland Clinic main campus and is the medical director of cardiac rehabilitation. Specialty Interests: Cardiology, preventive cardiology, hypertension (high… View more
Added: 2 months ago Source:  Cardiac Failure Review
Single-pill low-dose combination (LDC) therapy is an emerging strategy for improving blood pressure (BP) control in patients with hypertension.¹ Two new phase III trials, HM-APOLLO-301 and HM-APOLLO-302, have evaluated the efficacy and safety of an ultra-low-dose triple combination pill compared with standard-dose monotherapy as an initial treatment for mild-to-moderate hypertension… View more